[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659367":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":31,"studyPopulation":32,"armGroups":27,"interventions":33,"overallOfficials":27,"centralContacts":37,"locations":47,"responsibleParty":142,"collaborators":27,"id":144,"slug":145,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":146,"sex":151,"minAge":152,"maxAge":27,"enrollmentInfo":153,"targetDuration":27,"studyType":156,"phases":27,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":166,"whyStopped":27,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":27},[9],{"measure":10,"description":11,"timeFrame":12},"Clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months before MRI (Glasgow Outcome Scale Extended (GOSE \u003C5)","The primary outcome measure is the clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months before MRI (Glasgow Outcome Scale Extended (GOSE \\\u003C5). Two clinicians will be interviewed the day before or the day of the brain MRI using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis.\n\nThe clinician prognosis will be a number between 0 and 100, given by the clinician after this short explanation. \"Now that you have all prognostic factors in mind, we would like your estimate of the patient's risk of an unfavorable outcome, on a scale of 0 to 100. This refers to a person who is unable to go shopping or travel independently, and who is unable to live independently, corresponding to a GOSE less than 5, one year after their brain injury.\" We will use the average of the two prognoses to construct the ROC curve.","1 day before or the day of the MRI and 12 months after the brain injury",[14,18,21,24],{"measure":15,"description":16,"timeFrame":17},"Diffusion tensor Imaging's ROC curve for predicting unfavorable patient outcomes at 12 months (Glasgow Outcome Scale Extended (GOSE \u003C5).","Prediction of the risk of unfavourable outcome (GOSE \\\u003C 5) by a statistical toll (Support vector machine) published in 2026 (Puybasset et al 2026 PMID : 41782003) using age, time between MRI and brain lesion as well as the mean and normalized value of the fractional anisotropy and mean diffusivity in the 17 regions of white matter defined by the Johns Hopkins Hospital Atlas.\n\nAs described above, the assessment of unfavorable neurological outcomes will be based on the GOSE score.","12 months",{"measure":19,"description":20,"timeFrame":17},"Clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months before MRI (Glasgow Outcome Scale Extended (GOSE \u003C4).","This secondary outcome measure is the clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months (Glasgow Outcome Scale Extended (GOSE \\\u003C4).\n\nTwo clinicians will be interviewed the day before or the day of the brain MRI using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis.\n\nThe clinician prognosis will be a number between 0 and 100, given by the clinician after this short explanation.\n\nAs described above, the assessment of unfavorable neurological outcomes will be based on the GOSE score.",{"measure":22,"description":23,"timeFrame":17},"Clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months after MRI results (Glasgow Outcome Scale Extended (GOSE \u003C5).","This secondary outcome measure is the clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months just after MRI prediction (the same day) (GOSE \\\u003C5).\n\nTwo clinicians will be interviewed the day after MRI prognosis using a questionnaire.\n\nThis questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis.\n\nThe clinician prognosis will be a number between 0 and 100, given by the clinician after this short explanation.\n\nAs described above, the assessment of unfavorable neurological outcomes will be based on the GOSE score.",{"measure":25,"description":26,"timeFrame":17},"Clinicians'ROC curve for predicting unfavorable patient outcomes at 12 months after MRI results (Glasgow Outcome Scale Extended (GOSE \u003C4).","This secondary outcome measure is the clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months just after MRI prediction (the same day) (GOSE \\\u003C4).\n\nTwo clinicians will be interviewed the day after MRI prognosis using a questionnaire.\n\nThis questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis.\n\nThe clinician prognosis will be a number between 0 and 100, given by the clinician after this short explanation.\n\nAs described above, the assessment of unfavorable neurological outcomes will be based on the GOSE score.",null,{"allocation":27,"interventionModel":27,"interventionModelDescription":27,"primaryPurpose":27,"observationalModel":29,"timePerspective":30,"maskingInfo":27},"COHORT","PROSPECTIVE","With a mortality rate of over 13% in the neuro-intensive care unit, 86% of which are related to the withdrawal of active treatment, predicting a reliable neurological prognosis is of paramount importance in neuro-intensive care to help clinicians inform family members appropriately and tailor care to the patient's presumed wishes. This allows for the justification of intensive resuscitation treatments in patients with a presumed good prognosis and, conversely, avoids keeping patients with an unfavorable neurological prognosis alive against their presumed wishes.\n\nCurrent guidelines advocate a multimodal neuroprognostic approach, where the clinician synthesizes prognoctic factors from clinical examination, EEG, plasma or CSF biomarkers, and imaging to collaboratively develop an individualized prognosis, even though no study has evaluated the quality of this multimodal prognosis. Furthermore, the existing variability depending on the nosological contexte makes this approach complex and likely difficult to reproduce. Brain MRI is an important tool for neuroprognostication in patients with neurological injuries, and for this reason, it is commonly used in clinical pratice as part of a multimodal approach.\n\nMore specifically, brain MRI with diffusion tensor imaging sequences is validated prognostic tool in post anoxic coma, traumatic brain injury, and more recently in spontaneous hemorrhagic stroke, subarachnoid hemorrhage, and hypoglycemia. It allows for relatively precise classification of patients after cerebral anoxia or traumatic brain injury into 3 categories : those with an unfavorable outcome (specificity greater than 95%), those with an indeterminate outcome, and those with a favorable outcome (specificity greater than 95%).\n\nIt is currently being evaluated in the COMABASE study for its prognostic value in other cerebral pathologies (spontaneous hemorrhagic stroke, subarachnoid aneurysmal hemorrhage, and hypoglycemia).\n\nDespite its excellent discriminatory values (AUC 0.93), it has not been compared to the gold standard, namely multimodal neuroprognosis performed by a panel of clinicians.\n\nDescription of the study population:\n\nPrognostic uncertainty is crucial for determining the treatment of neurologically injured patients hospitalized in intensive care. Indeed, knowledge of an unfavorable outcome helps avoid situations of therapeutic obstinacy that deliver futile and unreasonable treatments, while conversely, knowledge of a favorable outcome allows for the intensification of rehabilitation care.\n\nWe wish to study the informational contribution of diffusion tensor imaging (DTI) to the clinician's prognostic development. To this end, we will study the degree of prognostic uncertainty eperienced by clinicians before DTI scans are performed to determine whether MRI helps reduce this uncertainty.\n\nThis research aims to evaluate the prognostic ability of clinicians prescribing diffusion tensor imaging (DTI), specifically the fractional anisotropy and mean diffusivity in the white matter, associated with patient age, and the time betwen the onset of symptoms and the MRI scan. It also aims to evaluate the predictive power of clinicians integrating multimodal signals (clinical finfings, EEG, and CT scan) regarding neurological prognosis at the time of the MRI scan. The clinicians' predictions will be assessed on the day of the MRI scan and a few hours prior to it, to ensure the closest possible comparison with the prognosis provided by MRI markers.\n\nWe need to recruit 220 patients and 70 clinicians across 8 intensives care units.\n\nThe planned duration of the research will be 3 years and 2 months, with an inclusion period of 2 years associated with a follow-up period of 14 months (12 months +\u002F- 2 months) in order to include a total of 220 patients.\n\nThe primary objective of this study is to compare the prognostic performance of two prescribing clinicians using diffusion tensor imaging (DTI) before and after the MRI scan.\n\nSecondary objectives are:\n\n* to study the informational gain of MRI in improving clinicians' predictions after obtaining the MRI results.\n* To study predicitive factors of the quality of the clinicians' prognosis, including: the time between the discontinuation of sedation and the MRI scan, the clinicians' experience, and the level of altered consciousness at the time of the MRI scan.\n* To study the concordance between the two clinicians' prognoses before the MRI scan and the concordance between the two clinicians' prognoses after receiving the MRI results.\n\nThe primary ouctome measure is the clinicians' ROC curve for predicting adverse patient ouctomes at 12 months (Glasgow Outcome Scale Extended (GOSE \\\u003C5).\n\nTwo clinicians will be interviewed the day before or the day of the brain MRI using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis.\n\nThe assessment of adverse neurological outcomes will be based on the GOSE score. To determine this score blinded to the prognosis established by the MRI and the clinicians, we will proceed as follows:\n\n\\- a phone call will be made, blinded to the prognosis made before the MRI and without knowledge of the prognosis established by diffusion tensor MRI, 12 months after the brain injury. This call will be made by a person qualified to administer the questionnaires, in order to obtain a GOSE score.\n\nWe will re-analyze the prognosis results of DTI to establish the ROC curve for this statistical tool.\n\n* Clinician prognosis before and immediately after MRI results\n* Data collection includes the time between the discontinuation of sedation and the MRI scan, the clinician's experience level, and the patient's level of consciousness at the time of the MRI to study their influence on the clinician's prognosic accuracy;\n* Diagnosis by both clinicians before and after MRI\n* Patient quality of life one year after the brain injury.\n\nThe study population:\n\nclinicians in intensive care following patients with brain injury who perform brain MRI for prognostic reasons within the framework of care and multimodal neuroprognosis.\n\nThe inclusion criteria are:\n\nFor clinicians:\n\n* Clinicians with a medical degree\n* Prescribers of DTI for the following patients\n\nFor patients :\n\n* Patients aged 18 years or older\n* Patients for whom a brain MRI with a DTI sequences is prescribed, during or following resuscitation as part of their care.\n* A close relative or trusted person informed of the research and who has not objected to the patient's participation in the study. Given the altered state of consciousness of these patients, the patient is unable to express their objection.\n\nThe non inclusion criteria are:\n\nFor clinicians:\n\n\\- Clinician's refusal to complete the study questionnaires\n\nFor patients:\n\n\\- DTI measurements (anisotropy fraction and mean diffusivity) not feasible before or after treatment\n\nStudy procedure:\n\nClinicians prescribing MRI scans will be informed of the study the day before or the day of the MRI scan, a few hours prior. If they do not object, they will be asked to complete the study questionniares. Note that a clinician may participate in the study for multiple patients\n\nOn the day of the MRI scan:\n\nThe patient's data for the research will be collected, including the type of brain lesion, the date of the brain lesion, the date sedation was discontinued, the detailed Glasgow Coma Scale score on the day or the day before the MRI scan, eye movement tracking and fluctuations in level of consciousness, and other standard variables (etiology of altered consciousness, demographic data).\n\nTwo clinicians will complete the research questionnaire assessing the patient's prognosis a few hours before the MRI scan on the same day.\n\nAs soon as the MRI results are obtained (on the same day if possible):\n\nThe same two clinicians will complete the research questionnaire assessing the patient's prognosis after receiving the MRI results.\n\nFollow-up of the population at 1 year (+\u002F- 2 months). If the patient is alive and not under legal guardianship, a telephone call will be made to inform the patient and ask for their consent to continue the research.\n\nThen, a Glasgow Outcomes Scale Extended (GOSE) will be administered to the patient or a relative, and a Medical Ouctomes study Short Form General Health Survey will be completed, blinded to the prognostic assessment established by diffusion tensor MRI and the clinicians.\n\nThe patient's progress data will be collected using the patient's medical record.\n\nDuration of participant participation and duration of the research:\n\nInclusion period: 2 years Duration of patient participation: maximum 14 months Duration of the research: 3 years and 2 months\n\nThe sample size calculation was performed with the secondary objective of comparing clinician prognosis to that of MRI. It was based on the sample size calculation described in the 2024 publication by Jung et al. for comparing two diagnostic tolls using paired data.\n\nWe calculated a sample size of 209 patients based on parameters collected from two previously publieshed studies on this topic:\n\n* an AUC of 0.80 for clinicians (Amzallag et al.)\n* an AUC of 0.90 for DTI MRI (Puybasset et al.)\n* an estimated prevalence of unfavorable outcomes in this population requiring multimodal assessment of 70 %\n* a correlation between the two diagnostic test of 0.5\n* an alpha risk of 0.05\n* a power of 90 %\n* estimating the number of missing data points on MRI or clinician predictions at 5%, we aim to include 220 patients.\n\nComparison using the DeLong method for paired studies between the Receiver Operating Characteristic (ROC) curve predicting an unfavorable outcome at 12 months, established by the predictive model based on fractional anisotropy values, mean white matter diffusivity, patient age, and the time between the brain lesion and the mean prediction established by a clinician in charge of the patient the day before the MRI.\n\nThis comparison will be performed on all patients and then on patients who survived the intensive care unit.\n\nThe agreement between the clinicians' predictions will be studied using intraclass correlation coefficients for paired measures.\n\nAll tests were two-sided, and p values \\\u003C 0.05 were considered statistically significant.\n\nPatients with missing data on MRI prognostic information clinician-pre-MRI prognosis, or GOSE score at one year will be excluded from the study. These patients will not be replaced, but we are accounting for this loss of of information in the sample size calculation, estimating it at approximately 5%","Intensive care clinicians who care for patients in the intensive care unit with brain injury and who perform brain MRI for prognostic purposes as part of patient care and multimodal neuroprognostics, as well as those patients.",[34],{"type":6,"name":35,"description":36,"armGroupLabels":27,"otherNames":27},"Questionnaire","Two clinicians will be interviewed the day before or the day of the brain MRI using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis.\n\nA phone call will be made, blinded to the prognosis made before the MRI and without knowledge of the prognosis established by diffusion tensor MRI, 12 months after the brain injury. This call will be made by a person qualified to administer the questionnaires, in order to obtain a GOSE score.",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":27,"email":42},"Rémy BERNARD, MD","CONTACT","+33 01 84 82 75 78","remy.bernard@aphp.fr",{"name":44,"role":40,"phone":45,"phoneExt":27,"email":46},"Pierre SIMEONE, MD PhD","+33 06 59 24 03 13","pierre.simeone@ap-hm.fr",[48,65,79,90,98,109,120,131],{"facility":49,"status":27,"city":50,"state":27,"zip":27,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Réanimation Polyvalente, AP-HM La Timone","Marseille","France","FR",{"type":54,"coordinates":55},"Point",[56,57],5.38107,43.29695,{"lat":57,"lon":56},[60,63],{"name":61,"role":40,"phone":62,"phoneExt":27,"email":46},"Pierre SIMEONE, MD, PhD","04 13 42 94 74",{"name":61,"role":64,"phone":27,"phoneExt":27,"email":27},"PRINCIPAL_INVESTIGATOR",{"facility":66,"status":27,"city":67,"state":27,"zip":27,"country":51,"countryCode":52,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Institut de cardiologie, réanimation médicale, hôpital Pitié-Salpêtrière","Paris",{"type":54,"coordinates":69},[70,71],2.3488,48.85341,{"lat":71,"lon":70},[74,78],{"name":75,"role":40,"phone":76,"phoneExt":27,"email":77},"Charles Edouard LUYT, MD","+33 01 42 16 83 24","charles-edouard.luyt@aphp.fr",{"name":75,"role":64,"phone":27,"phoneExt":27,"email":27},{"facility":80,"status":27,"city":67,"state":27,"zip":27,"country":51,"countryCode":52,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"Réanimation Institut de Cardiologie, chirurgie cardiaque, hôpital Pitié Salpêtrière",{"type":54,"coordinates":82},[70,71],{"lat":71,"lon":70},[85,89],{"name":86,"role":40,"phone":87,"phoneExt":27,"email":88},"Adrien BOUGLE, MD","01 42 16 29 91","adrien.bougle@psl.aphp.fr",{"name":86,"role":64,"phone":27,"phoneExt":27,"email":27},{"facility":91,"status":27,"city":67,"state":27,"zip":27,"country":51,"countryCode":52,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},"Service de réanimation Babinski, Hôpital Pitié Salpêtrière",{"type":54,"coordinates":93},[70,71],{"lat":71,"lon":70},[96,97],{"name":39,"role":40,"phone":41,"phoneExt":27,"email":42},{"name":39,"role":64,"phone":27,"phoneExt":27,"email":27},{"facility":99,"status":27,"city":67,"state":27,"zip":27,"country":51,"countryCode":52,"cosmosGeoPoint":100,"geoPoint":102,"contacts":103},"Service de Réanimation Eole, Hôpital Pitié Salpêtrière",{"type":54,"coordinates":101},[70,71],{"lat":71,"lon":70},[104,108],{"name":105,"role":40,"phone":106,"phoneExt":27,"email":107},"Julien MAYAUX, MD","+33 01 42 16 77 56","julien.mayaux@aphp.fr",{"name":105,"role":64,"phone":27,"phoneExt":27,"email":27},{"facility":110,"status":27,"city":67,"state":27,"zip":27,"country":51,"countryCode":52,"cosmosGeoPoint":111,"geoPoint":113,"contacts":114},"Service de Réanimation Gaston Cordier, Hôpital Pitié Salpêtrière",{"type":54,"coordinates":112},[70,71],{"lat":71,"lon":70},[115,119],{"name":116,"role":40,"phone":117,"phoneExt":27,"email":118},"Arthur JAMES, MD","+33 01 42 17 73 02","arthur.james@aphp.fr",{"name":116,"role":64,"phone":27,"phoneExt":27,"email":27},{"facility":121,"status":27,"city":67,"state":27,"zip":27,"country":51,"countryCode":52,"cosmosGeoPoint":122,"geoPoint":124,"contacts":125},"Service de réanimation Husson Mourrier, hôpital Pitié-Salpêtrière",{"type":54,"coordinates":123},[70,71],{"lat":71,"lon":70},[126,130],{"name":127,"role":40,"phone":128,"phoneExt":27,"email":129},"Antoine MONSEL, MD","+33 01 84 82 73 99","antoine.monsel@aphp.fr",{"name":127,"role":64,"phone":27,"phoneExt":27,"email":27},{"facility":132,"status":27,"city":67,"state":27,"zip":27,"country":51,"countryCode":52,"cosmosGeoPoint":133,"geoPoint":135,"contacts":136},"Service de Réanimation neurologie médicale, hôpital Pitié-Salpêtrière",{"type":54,"coordinates":134},[70,71],{"lat":71,"lon":70},[137,141],{"name":138,"role":40,"phone":139,"phoneExt":27,"email":140},"Benjamin ROHAUT, MD","+33 01 84 82 78 88","benjamin.rohaut@aphp.fr",{"name":138,"role":64,"phone":27,"phoneExt":27,"email":27},{"type":143,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100659367","description-of-clinicians-predictive-abilities-before-and-after-a-diffusion-tensor-imaging-dti-100659367",false,"NCT07863414","Description of Clinicians' Predictive Abilities Before and After a Diffusion Tensor Imaging (DTI)","Neuro-FORECAST","Inclusion Criteria:\n\n* For clinicians:\n* Clinicians with a medical degree\n* Prescribers of DTI for the following patients\n\nFor patients :\n\n* Patients aged 18 years or older\n* Patients for whom a brain MRI with a DTI sequences is prescribed, during or following resuscitation as part of their care.\n* A close relative or trusted person informed of the research and who has not objected to the patient's participation in the study. Given the altered state of consciousness of these patients, the patient is unable to express their objection.\n\nExclusion Criteria:\n\nFor clinicians - Clinician's refusal to complete the study questionnaires\n\nFor patients:\n\n\\- DTI measurements (anisotropy fraction and mean diffusivity) not feasible before or after treatment","ALL","18 Years",{"count":154,"type":155},220,"ESTIMATED","OBSERVATIONAL","With a mortality rate of over 13% in the neuro-intensive care unit, 86% of which are related to the withdrawal of active treatment, predicting a reliable neurological prognosis is of paramount importance in neuro-intensive care to help clinicians inform family members appropriately and tailor care to the patient's presumed wishes. This also helps justify aggressive resuscitation in patients with a presumed good prognosis and, conversely, avoid keeping patients with a poor neurological prognosis alive against their presumed wishes.\n\nCurrent guidelines recommend multimodal neuro-prognostication, in which the clinician synthesizes prognostic data from the clinical examination, EEG, plasma or CSF biomarkers, and imaging to collaboratively develop an individualized prognosis, even though no study has evaluated the quality of this multimodal prognosis. Furthermore, existing variations depending on the nosological context make this approach complex and likely difficult to replicate.\n\nBrain MRI is an important tool for neuroprognostics in patients with neurological injuries, and for this reason it is commonly used in clinical practice as part of this multimodal approach.\n\nMore specifically, brain MRI with diffusion tensor sequences is a validated prognostic tool in post-anoxic coma and traumatic brain injury, as well as, more recently, in subarachnoid hemorrhage, strokes, and hypoglycemia. However, it has not yet been compared to multimodal neuroprognostics performed by the clinician.\n\nThe primary objective is to compare the prognostic performance of two prescribing clinicians with diffusion tensor MRI before and after the MRI scan is performed.\n\nPrimary outcome measure: to compare the prognostic performance regarding unfavorable outcomes (Glasgow Outcome Scale Extended \\\u003C 5) at 12 months between the two prescribing clinicians and diffusion tensor MRI before and after the MRI scan is performed.\n\nA secondary objective will be, among other things, to study the informational gain provided by MRI in improving clinicians' predictions after receiving the MRI results.\n\nIntensive care clinicians constitute the target population. These are clinicians caring for an intensive care patient with a brain injury who order a brain MRI for prognostic purposes as part of patient care and multimodal neuroprognostics.\n\nOn the day of the MRI, two clinicians will complete the research questionnaire assessing the patient's prognosis the day before or a few hours before the MRI (on the same day). Then, as soon as the MRI results are available, the same two clinicians will complete the same questionnaire assessing the patient's prognosis after reviewing the MRI results. Patient data regarding the pathology and prognostic factors will be collected at this time.\n\nFinally, surviving patients will be interviewed at 1 year regarding their independence using the Glasgow Outcome Scale Extended (GOSE) and their quality of life using the Medical Outcomes Study Short Form General Health Survey (SF-12) via a telephone call.\n\nWe plan to include 220 patients and approximately 70 clinicians across 8 recruiting centers over a 2-year enrollment period. With a 12-month follow-up period, the total duration of the study will be 3 years.\n\nThe statistical analysis will include a description of clinicians' ability to distinguish patient prognosis by measuring the area under the Receiver Operating Characteristic (ROC) curve, or AUC. The prediction concerns an unfavorable outcome, defined as a GOSE score of 1 to 4. Since we had no pre-study data on clinicians' performance in predicting an unfavorable outcome at the time of a prognostic MRI, the inclusion target was set based on data from a previous study at 220 patients, which corresponds to the number of patients we planned to enroll over a 2-year period.",[159],"Diffusion Tensor Imaging Prognosis",[161,162,163,164,165],"diffusion tensor imaging","delayed awakening","clinicians'prognosis","prediction","brain injury","NOT_YET_RECRUITING","2026-10-02",{"date":169,"type":170},"2026-10-07","ACTUAL",{"date":172,"type":155},"2026-11",{"date":174,"type":155},"2030-01",{"name":5,"class":6},8]